Aurobindo Pharma Shares Soar 3% as Arm Secures VAI from USFDA 

Shares of Aurobindo Pharma Ltd soared 3% on 20 March after the company announced that its wholly owned subsidiary, Apitoria Pharma Pvt Ltd, has acquired a ‘Voluntary Action Indicated’ (VAI) classification from the US Food and Drug Administration (USFDA) for its Unit-V production facility.

The USFDA investigated the API manufacturing facility in Telangana from 1 December to 12 December 2025, and issued a Form 483 with three observations.

Subsequently, the unit obtained an Establishment Inspection Report (EIR) designating the facility as VAI, indicating that the inspection was completed.

The VAI designation indicates that, while certain observations were made during the inspection, they do not merit regulatory or enforcement action by the USFDA. The development signifies the end of the facility’s inspection process.

Following an inspection earlier this week, the USFDA designated another of the company’s subsidiaries, Eugia Pharma Specialities Ltd, as ‘Official Action Indicated’ (OAI).

In the December quarter, Aurobindo Pharma’s net profit increased by 7.5% to Rs 909.8 crore from Rs 846 crore. This included a one-time cost of Rs 65 crore due to a change in the labour code.

The revenue for the quarter increased by 8.4% YoY to Rs 8,646 crore from Rs 7,979 crore in Q3FY25. EBITDA increased 12.4% to Rs 1,773.6 crore from Rs 1,577.5 crore last year. The EBITDA margin rose to 20.5% from 19.8% in the same period last year.

At 12:24 pm, the shares of Aurobindo Pharma were trading 3.05% higher at Rs 1,285.60 on NSE.

The future of investing is here!
Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!

The post Aurobindo Pharma Shares Soar 3% as Arm Secures VAI from USFDA  appeared first on Equitypandit.